Acute bilateral hypotropia and esotropia complex as first manifestation of multiple sclerosis: a case report

1 Barnes D, McDonald WI. The ocular manifestations of multiple sclerosis. 2. Abnormalities of eye movements. J Neurol Neurosurg Psychiatry. 1992;55(10):863-868. doi:10.1136/jnnp.55.10.863.

2 Bentley PI, Kimber T, Schapira AH. Painful third nerve palsy in MS. Neurology. 2002;58(10):1532.

doi:10.1212/wnl.58.10.1532.

3 Barr D, Kupersmith MJ, Turbin R, Bose S, Roth R. Isolated sixth nerve palsy: an uncommon presenting

sign of multiple sclerosis. J Neurol. 2000;247(9):701–704. doi:10.1007/s004150070114.

Nagoya J. Med. Sci. 85. 822–827, 2023

826

doi:10.18999/nagjms.85.4.822

Bilateral hypotropia and esotropia in MS

4 Milea D, Napolitano M, Dechy H, Le Hoang P, Delattre JY, Pierrot-Desseilligny C. Complete bilateral

horizontal gaze palsy disclosing multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;70(2):252–255.

doi:10.1136/jnnp.70.2.252.

5 Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the

McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi:10.1016/S1474-4422(17)30470-2.

6 Wall M, Wray SH. The one-and-a-half syndrome: a unilateral disorder of the pontine tegmentum: a study

of 20 cases and review of the literature. Neurology. 1983;33(8):971–980. doi:10.1212/wnl.33.8.971.

7 Newman NJ, Lessell S. Isolated pupil-sparing third-nerve palsy as the presenting sign of multiple sclerosis.

Arch Neurol. 1990;47(7):817–818. doi:10.1001/archneur.1990.00530070117021.

8 Müri RM, Chermann JF, Cohen L, Rivaud S, Pierrot-Deseilligny C. Ocular motor consequences of damage

to the abducens nucleus area in humans. J Neuroophthalmol. 1996;16(3):191–195.

9 Kipfer S, Crook DW. Isolated bilateral horizontal gaze palsy as first manifestation of multiple sclerosis.

Mult Scler. 2014;20(6):754–755. doi:10.1177/1352458513518627.

10 Serra A, Derwenskus J, Downey DL, Leigh RJ. Role of eye movement examination and subjective visual

vertical in clinical evaluation of multiple sclerosis. J Neurol. 2003;250(5):569–575. doi:10.1007/s00415-0031038-8.

11 Bolaños I, Lozano D, Cantú C. Internuclear ophthalmoparesis: causes and long-term follow-up in 65 patients.

Acta Neurol Scand. 2004;110(3):161–165. doi:10.1111/j.1600-0404.2004.00278.x.

12 Keane JR. Internuclear ophthalmoparesis: unusual causes in 114 of 410 patients. Arch Neurol.

2005;62(5):714–717. doi:10.1001/archneur.62.5.714.

13 Rieckmann P, Toyka KV, Bassetti C, et al. Escalating immunotherapy of multiple sclerosis – new aspects

and practical application. J Neurol. 2004;251(11):1329–1339. doi:10.1007/s00415-004-0537-6.

14 Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175–187. doi:10.1001/jama.2018.20588.

15 Beiki O, Frumento P, Bottai M, Manouchehrinia A, Hillert J. Changes in the risk of reaching multiple

sclerosis disability milestones in recent decades: A nationwide population-based cohort study in Sweden.

JAMA Neurol. 2019;76(6):665–671. doi:10.1001/jamaneurol.2019.0330.

16 Linker RA, Haghikia A. Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place

in therapy. Ther Adv Chronic Dis. 2016;7(4):198–207. doi:10.1177/2040622316653307.

References End

Nagoya J. Med. Sci. 85. 822–827, 2023

827

doi:10.18999/nagjms.85.4.822

...